Biodegradable Stents in the Management of Stenoses of the Large Airways
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02620319 |
Recruitment Status : Unknown
Verified December 2015 by Ludek Stehlik, Thomayer Hospital.
Recruitment status was: Active, not recruiting
First Posted : December 3, 2015
Last Update Posted : June 17, 2016
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Tracheal Stenosis | Device: SX-ELLA Stent DV Tracheal (DV Stent) | Not Applicable |

Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 30 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Biodegradable Stents in the Management of Stenoses of the Large Airways |
Study Start Date : | May 2013 |
Estimated Primary Completion Date : | December 2016 |
Estimated Study Completion Date : | December 2016 |
Arm | Intervention/treatment |
---|---|
Experimental: biodegradable stent
endoscopic implantation of biodegradable airway stent, the SX-ELLA Stent DV Tracheal (DV Stent)
|
Device: SX-ELLA Stent DV Tracheal (DV Stent)
The trachea is intubated with a rigid bronchoscope while participants are placed under total intravenous anesthesia and jet ventilation. The delivery apparatus containing the stent is introduced through a rigid tube to the desired depth under visual control. Then the stent is deployed and its position is determined and, if necessary, stent is repositioned using rigid forceps. In-stent balloon dilation is carried out. If needed, thoracic surgeon can secure the stent in place via external (percutaneous) fixation: one suture is passed through the stent, the tracheal wall, soft tissues, and skin; the suture is then knotted on the skin of the neck. The suture is removed two to three weeks after implantation.
Other Name: DV Stent |
- airway patency during the presence of the stent in the airways [ Time Frame: residence time of the stent in the airways, i.e. as long as no stent material is found, up to 180 days after implantation, since then the stent is not considered to provide any mechanical support ]Scheduled bronchoscopies, trachea is, for the purposes of the study, classified according to Freitag's recommended adapted classification system (Freitag L. et al. A proposed classification system of central airway stenosis, Eur Respir J 2007; 30:7-12).
- number of complications: infection, bleeding, migration, obstructive granulation tissue formation, sudden restenosis (of any origin, unexpected in relation to the degree of the stent degradation) [ Time Frame: residence time of the stent in the airways (i.e. as long as no stent material is found, up to 180 days after implantation, since then the stent is not considered to provide any mechanical support) and 6 months thereafter ]
- evaluation of forced expiratory volume in 1 second (FEV1) [ Time Frame: residence time of the stent in the airways (i.e. as long as no stent material is found, up to 180 days after implantation, since then the stent is not considered to provide any mechanical support) and 6 months thereafter ]FEV1 (in liters and % predicted values) measurements within follow-ups.
- evaluation of forced vital capacity (FVC) [ Time Frame: residence time of the stent in the airways (i.e. as long as no stent material is found, up to 180 days after implantation, since then the stent is not considered to provide any mechanical support) and 6 months thereafter ]FVC (in liters and % predicted values) measurements within follow-ups.
- airway patency after complete degradation of the stent or loss of majority support functions [ Time Frame: six months, beginning after identifying the complete degradation of the stent or 180 days after implantation ]Scheduled bronchoscopies, trachea is, for the purposes of the study, classified according to Freitag's recommended adapted classification system (Freitag L. et al. A proposed classification system of central airway stenosis, Eur Respir J 2007; 30:7-12).

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- significant large airway stenoses
- benign tracheobronchial stenosis of any origin in participants who can not go for surgery, or who refuse surgical treatment
- benign tracheobronchial stenoses of any origin when the surgery is planed after some delay, benign tracheobronchial stenoses when the effect of anti- inflammatory or anti-infective treatment is expected
- malignant tracheobronchial stenoses due to extrinsic compression when exhausted curative modalities
- malignant stenoses from extrinsic compression in participants undergoing the actinotherapy or receiving systemic anticancer therapy
Exclusion Criteria:
- stenoses of any origin which can be treated primarily surgically
- stenoses caused by intraluminal growth of tumor, tracheoesophageal or bronchoesophageal fistulas
- pregnancy

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02620319
Czech Republic | |
Department of Respiratory Diseases and Tuberculosis, University Hospital Olomouc | |
Olomouc, Czech Republic, 779 00 | |
Department of Respiratory Medicine, Thomayer Hospital | |
Prague, Czech Republic, 140 59 | |
Department of Pneumology, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital | |
Prague, Czech Republic, 150 06 |
Principal Investigator: | Ludek Stehlik, MUDr. | Department of Respiratory Medicine, Thomayer Hospital, Videnska 800, 140 59 Praha 4 | |
Study Director: | Miloslav Marel, Prof. MUDr. | Department of Pneumology, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital | |
Study Director: | Vitezslav Kolek, Prof. MUDr. | Department of Respiratory Diseases and Tuberculosis, University Hospital Olomouc | |
Study Director: | Martina Vasakova, Prof. MUDr. | Department of Respiratory Medicine, Thomayer Hospital, Videnska 800, 140 59 Praha 4 |
Other Publications:
Responsible Party: | Ludek Stehlik, MUDr., Thomayer Hospital |
ClinicalTrials.gov Identifier: | NCT02620319 |
Other Study ID Numbers: |
NT 14146-3/2013 NT14146 ( Other Grant/Funding Number: Internal Grant Agency of the Czech Ministry of Health ) |
First Posted: | December 3, 2015 Key Record Dates |
Last Update Posted: | June 17, 2016 |
Last Verified: | December 2015 |
bronchoscopy polydioxanone absorbable implants stents |
Tracheal Stenosis Constriction, Pathologic Pathological Conditions, Anatomical Tracheal Diseases Respiratory Tract Diseases |